1 active not recruiting, 1 enrolling by invitation, 1 not yet recruiting, 1 recruiting. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 3 | Enrolling by invitation 1, Not yet recruiting 1, Recruiting 1 |
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Safety and Efficacy of Prime Editing (PM647a) in Participants With Alpha-1 Antitrypsin Deficiency PM647a - Alpha-1 Antitrypsin Deficiency, Alpha-1 Antitrypsin Deficiency-associated Lung Disease | Phase 1 / Phase 2 | Not yet recruiting | Prime Medicine, Inc. | 54 | 2026-10-01 | 2026-10-21 |
| A Study of the Safety and Efficacy of Prime Editing (PM577) in Participants With Wilson Disease (WD) PM577a - Wilson Disease, Wilson's Disease | Phase 1 / Phase 2 | Recruiting | Prime Medicine, Inc. | 42 | 2026-09-01 | 2026-10-01 |
| Prescreening Study to Identify Potential Wilson Disease Participants for Gene-Editing Clinical Trial Wilson Disease | Active not recruiting | Prime Medicine, Inc. | 30 | 2025-12-29 | 2026-05-12 | |
| A Study of the Safety and Efficacy of Prime Editing (PM359) in Participants With p47phox Autosomal Recessive Chronic Granulomatous Disease (CGD ) PM359 - Chronic Granulomatous Disease, Granulomatous Disease, Chronic | Phase 1 / Phase 2 | Enrolling by invitation | Prime Medicine, Inc. | 12 | 2024-10-17 | 2026-04-06 |
Hepatolenticular Degeneration (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Granulomatous Disease, Chronic (1) · Liver Diseases (1) · Metabolic Diseases (1) · Metabolism, Inborn Errors (1) · Metal Metabolism, Inborn Errors (1) · Nutritional and Metabolic Diseases (1) · alpha 1-Antitrypsin Deficiency (1)
United States (3) · Canada (1) · New Zealand (1) · United Kingdom (1)
2025 (1)